



1646

Atty. Dkt. No. SALK1510-3
(088802-8704)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Evans et al.

Title: A FAMILY OF
TRANSCRIPTIONAL CO-
REPRESSORS THAT INTERACT
WITH NUCLEAR HORMONE
RECEPTORS AND USES
THEREFOR

Appl. No.: 09/522,753

Filing Date: 03/10/2000

Examiner: E. O'Hara

Art Unit: 1646

CERTIFICATE OF MAILING
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below.

Stephen E. Reiter

(Printed Name)

July 30, 2001

(Date of Deposit)

RECEIVED

AUG 06 2001

TECH CENTER 1600/2900

Commissioner for Patents
BOX NON-FEE AMENDMENT
Washington, D.C. 20231

Sir:

Transmitted herewith is a Response in the above-identified application.

Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a Small Entity statement previously submitted.

Small Entity statement is enclosed.

The fee required for additional claims is calculated below:

	Claims as Amended	Previously Paid For	Extra Claims Present	Rate	Additional Claims Fee
Total Claims:	26	—	26	= 0 x \$18.00 =	\$0.00
Independents:	5	—	5	= 0 x \$80.00 =	\$0.00
First presentation of any Multiple Dependent Claims:				+ \$270.00 =	\$0.00
				CLAIMS FEE TOTAL: =	\$0.00

RECEIVED

AUG 06 2001

Atty. Dkt. No. SALK1510-3

TECHNICAL (088802-8704) ER 1600/2900

Applicant hereby petitions for an extension of time under 37 C.F.R. §1.136(a) for the total number of months checked below:

<input type="checkbox"/> Extension for response filed within the first month:	\$110.00	\$0.00
<input type="checkbox"/> Extension for response filed within the second month:	\$390.00	\$0.00
<input type="checkbox"/> Extension for response filed within the third month:	\$890.00	\$0.00
<input type="checkbox"/> Extension for response filed within the fourth month:	\$1,390.00	\$0.00
<input type="checkbox"/> Extension for response filed within the fifth month:	\$1,890.00	\$0.00
	EXTENSION FEE TOTAL:	\$0.00
	CLAIMS AND EXTENSION FEE TOTAL:	\$0.00
<input type="checkbox"/> Small Entity Fees Apply (subtract ½ of above):		\$0.00
	TOTAL FEE:	\$0.00

Please charge Deposit Account No. 50-0872 in the amount of \$ _____. A duplicate copy of this transmittal is enclosed.

A check in the amount of \$ _____. is enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date July 30, 2001

By 

FOLEY & LARDNER
402 West Broadway
23rd Floor
San Diego, California 92101-3542

Stephen E. Reiter
Attorney for Applicant
Registration No. 31,192

Telephone: (619) 685-3542
Facsimile: (619) 234-3510

RECEIVED

AUG 06 2001

PATENT

TECH CENTER 1600 Attorney Docket No.: SALK1510-3
(088802-8704)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Evans et al.

Application No.: 09/522,723

Filing Date: March 10, 2000

For: A FAMILY OF TRANSCRIPTIONAL CO-
REPRESSORS THAT INTERACT WITH
NUCLEAR HORMONE RECEPTORS
AND USES THEREFOR

Group Art Unit: 1646

Examiner: E. O'Hara

CERTIFICATION UNDER 37 CFR § 1.8

I hereby certify that the documents referred to as enclosed herein
are being deposited with the United States Postal Service as first
class mail on the date below, in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231

Stephen E. Reiter _____
Name of person mailing paper

Steph E. _____
Signature _____
July 30, 2001 _____
Date

Commissioner for Patents
Washington, D.C. 20231

RESPONSE

Sir:

Responsive to the Office Action mailed June 29, 2001 (Paper No. 7), please consider the following remarks.